In breast cancer, higher expression of IL-17 is linked with greater probability for recurrence, greater chemotherapy resistance (to docetaxel), shorter disease free survival, and poor prognosis [43], which suggests that local IL-17A might be used to monitor disease progression and response to therapy. This evidence concerns the gene IL17A and breast cancer.